IFCR-Lilly Agreement will Allow More Tuberculosis Program Funding
The International Federation of Red Cross and Red Crescent Societies (Geneva, Switzerland) and Eli Lilly and Company (Indianapolis, IN) have signed an agreement that will allow an eight-fold increase in the number of International Federation-supported programs to fight multidrug-resistant tuberculosis (MDR-TB) over the next four years.
The International Federation of Red Cross and Red Crescent Societies (Geneva, Switzerland) and Eli Lilly and Company (Indianapolis, IN) have signed an agreement that will allow an eight-fold increase in the number of International Federation-supported programs to fight multidrug-resistant tuberculosis (MDR-TB) over the next four years.
Lilly’s $1.6 million contribution will finance programs between 2008 and 2011. In 2008 alone, the International Federation will expand its support to 10 additional MDR-TB programs in Kazakhstan, Uzbekistan, Romania, Georgia, Kenya, Mozambique, and South Africa, for a total of 14 MDR-TB programs. The first phase of the International Federation and Lilly MDR-TB Program was implemented from 2004 to 2007 in three pilot countries.
Red Cross and Red Crescent TB programs include providing patients with care, food and support, educating the community about the spread and symptoms of tuberculosis, detecting new cases through surveillance, and addressing the stigma associated with the disease.
Eli Lilly release International Red Cross and Red Crescent Movement web site
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
